Quick links
Member links
Patients links
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Jun 1, 2021
The Impact of Plasma-Derived Therapies in Europe: The Health and Economic Case for Ensuring Sustainable Supply
Plasma-derived therapies are therapies derived from human plasma. They are manufactured using a fractionation process where the relevant proteins in plasma are separated out.
All
Publication
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6452a91ce4031b0eac4db789_copenhagen-economics_the-impact-of-plasma-derived-therapies-in-europe_june-2021.pdf
Jun 1, 2021
The Impact of Plasma-Derived Therapies in Europe: The Health and Economic Case for Ensuring Sustainable Supply
Plasma-derived therapies are therapies derived from human plasma. They are manufactured using a fractionation process where the relevant proteins in plasma are separated out.
All
Publication
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6452a91ce4031b0eac4db789_copenhagen-economics_the-impact-of-plasma-derived-therapies-in-europe_june-2021.pdf
Apr 21, 2021
The revision of the EU Blood Directive: How to enhance plasma collection by getting more donors via increased regulatory efficiency?
The online event entitled “The revision of the EU Blood Directive: How to enhance plasma collection by getting more donors via increased regulatory efficiency?”, organized and hosted by Member of the European Parliament (MEP) Sirpa Pietikäinen took place on April 21, 2021.
All
Presentation
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6452a9246257dcb88916f0a7_Report_How_to_enhance_plasma_collection_April_2021.pdf
Apr 21, 2021
The revision of the EU Blood Directive: How to enhance plasma collection by getting more donors via increased regulatory efficiency?
The online event entitled “The revision of the EU Blood Directive: How to enhance plasma collection by getting more donors via increased regulatory efficiency?”, organized and hosted by Member of the European Parliament (MEP) Sirpa Pietikäinen took place on April 21, 2021.
All
Presentation
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6452a9246257dcb88916f0a7_Report_How_to_enhance_plasma_collection_April_2021.pdf
Apr 1, 2021
About PPTA
The Plasma Protein Therapeutics Association (PPTA) represents the manufacturers of plasma-derived and recombinant analog therapies (collectively, “plasma protein therapies”) as well as plasma donation centers who collect source plasma. These therapies are used by people worldwide to treat a variety of rare diseases and serious medical conditions. PPTA members provide about 80 percent of the plasma protein therapies for the United States market.
All
Fact sheets
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64529e2c67f110401c2588ff_About_PPTA.pdf
Apr 1, 2021
About PPTA
The Plasma Protein Therapeutics Association (PPTA) represents the manufacturers of plasma-derived and recombinant analog therapies (collectively, “plasma protein therapies”) as well as plasma donation centers who collect source plasma. These therapies are used by people worldwide to treat a variety of rare diseases and serious medical conditions. PPTA members provide about 80 percent of the plasma protein therapies for the United States market.
All
Fact sheets
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64529e2c67f110401c2588ff_About_PPTA.pdf
Mar 31, 2021
PPTA Supports California AB 392
The Plasma Protein Therapeutics Association (PPTA) would like to thank you for authoring Assembly Bill 392.
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6453f688a121567c7026889d_PPTA%20Supports%20AB%20392%20Nazarian.pdf
Mar 31, 2021
PPTA Supports California AB 392
The Plasma Protein Therapeutics Association (PPTA) would like to thank you for authoring Assembly Bill 392.
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6453f688a121567c7026889d_PPTA%20Supports%20AB%20392%20Nazarian.pdf
No results found